Libtayo® (cemiplimab for injection) Now Reimbursed in Québec for Advanced Non-Small Cell Lung Cancer
TORONTO, Oct. 30, 2025 /CNW/ - Regeneron Canada Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by Régie de l'assurance ...
CNW/ - Company announced today that Libtayo® (cemiplimab for injection) is now reimbursed by public drug programs in Ontario, ...
3h
OPKO Health, Inc.: OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from ...
Kiniksa Pharmaceuticals leverages ARCALYST as it is a first-in-class FDA-approved treatment for recurrent pericarditis. Read ...
PURE Engagement announces 2025 patient support programme award winners across major therapeutic areas: Cedar Knolls, New Jersey Thursday, October 30, 2025, 13:00 Hrs [IST] PURE En ...
Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be sharing a poster ...
Zacks Investment Research on MSN
OPK Q3 Earnings Beat Estimates, Sales Miss, Gross Margin Expands
OPKO Health, Inc. OPK posted earnings per share of 3 cents for the third quarter of 2025, flat year over year. Earnings beat ...
Apogee Therapeutics, Inc. targets atopic dermatitis with APG777, aiming to outperform Dupixent. Learn more about APGE stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback